Highly purified eicosapentaenoic acid may increase low-density lipoprotein particle size by improving triglyceride metabolism in patients with hypertriglyceridemia

Circulation Journal

Volumn 77, Issue 9, 2013, Pages 2349-2357

  Tani, Shigemasa ^a,b   Nagao, Ken ^a,b   Matsumoto, Michiaki ^a,b   Hirayama, Atsushi ^b  

^a SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery disease; Coronary risk factor; Fatty acid; Lipid; Lipoprotein

Indexed keywords

APOLIPOPROTEIN; ARACHIDONIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; OPEN STUDY; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; CORONARY ARTERY DISEASE; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; PROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 84882745935     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1401     Document Type: Article

References (35)

1. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fsh consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985; 312: 1205-1209.
2. Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006; 113: 195-202.
3. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. [Errata in Lancet 2001; 357: 642 and Lancet 2007; 369: 106.] Lancet 1999; 354: 447-455.
4. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279: 23-28.
5. Mozaffarian D, Lemaitre RN, King IB, Song X, Spiegelman D, Sacks FM, et al. Circulating long-chain ω-3 fatty acids and incidence of congestive heart failure in older adults: The cardiovascular health study: A cohort study. Ann Intern Med 2011; 155: 160-170.
6. Hara M, Sakata Y, Nakatani D, Suna S, Usami M, Matsumoto S, et al. Low levels of serum n-3 polyunsaturated fatty acids are associated with worse heart failure-free survival in patients after acute myocar-dial infarction. Circ J 2012; 77: 153-162.
7. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011; 58: 2047-2067.
8. Gao JY, Yasuda S, Tsuburaya R, Ito Y, Shiroto T, Hao K, et al. Long-term treatment with eicosapentaenoic acid ameliorates myocardial ischemia-reperfusion injury in pigs in vivo: Involvement of Rho-kinase pathway inhibition. Circ J 2011; 75: 1843-1851.
9. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090-1098.
10. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 2009; 73: 1283-1290.
11. Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb 2011; 18: 99-107.
12. Kwiterovich PO Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that infuence low-density lipoprotein heterogeneity. Am J Cardiol 2002; 90: 30i-47i
13. St-Pierre AC, Cantin B, Dagenais GR, Mauriège P, Bernard PM, Després JP, et al, Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25: 553-559.
14. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of infammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
15. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, et al. Estimation of glomerular fltration rate by the MDRD study equation modifed for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
16. Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglyc-erides and small dense LDL: The twin Achilles heels of the Friede-wald formula. Clin Biochem 2003; 36: 499-504.
17. Mishima Y, Ando M, Kuyama F, Ishioka T, Kihata M. A simple method for identifying particle size of low-density lipoprotein using PAG electrophoresis: Comparison between LipoPhor and Lipoprint LDL systems. J Jpn Atherscler Soc 1997; 25: 67-70.
18. Hirano T, Ito Y, Yoshino G. Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb 2005; 12: 67-72.
19. Nakano T, Inoue I, Seo M, Takahashi S, Awata T, Komoda T, et al. Rapid and simple profling of lipoproteins by polyacrylamide-gel disc electrophoresis to determine the heterogeneity of low-density lipo-proteins (LDLs) including small, dense LDL. Recent Pat Cardiovasc Drug Discov 2009; 4: 31-36.
20. Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol 2008; 102: 1040-1045.
21. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 2011; 123: 2292-2333.
22. Cottin SC, Sanders TA, Hall WL. The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 2011; 70: 215-231.
23. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Best JD, et al. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care 2003; 26: 253.
24. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, et al. Purifed eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71: 1085-1094.
25. Satoh N, Shimatsu A, Kotani K, Sakane N, Yamada K, Suganami T, et al. Purifed eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007; 30: 144-146.
26. Oelrich B, Dewell A, Gardner CD. Effect of fsh oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults. Nutr Metab Cardiovasc Dis 2013; 23: 350-357.
27. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial). Am J Cardiol 2011; 108: 682-690.
28. Olano-Martina E, Anila E, Caslakeb MC, Packardb CJ, Bedfordb D, Stewartb G, et al, Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fsh oil. Atherosclerosis 2010; 209: 104-110.
29. Domei T, Yokoi H, Kuramitsu S, Soga Y, Arita T, Ando K, et al. Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J 2012; 76: 423-429.
30. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Effcacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
31. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis. JAMA 2012; 308: 1024-1033.
32. Roche HM, Gibney MJ. Long-chain n-3 polyunsaturated fatty acids and triacylglycerol metabolism in the postprandial state. Lipids 1999; 34(Suppl): S259-S265.
33. Metcalf RG, James MJ, Gibson RA, Edwards JR, Stubberfeld J, Stuklis R, et al. Effects of fish-oil supplementation on myocardial fatty acids in humans. Am J Clin Nutr 2007; 85: 1222-1228.
34. Yanagisawa N, Shimada K, Miyazaki T, Kume A, Kitamura Y, Ichikawa R, et al. Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area. J Atheroscler Thromb 2010; 17: 285-294.
35. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, et al. Development of a rapid, quantitative method for LDL sub-fractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 2001; 47: 266-274.